[Efficacy of phosphodiesterase inhibitors in the treatment of patients with organic erectile dysfunction: a comparative study].

Abstract

Currently available three highly selective and effective PDE-5 inhibitors (sildenafil, tadalafil and wardenafil) are comparable by PDE-5 inhibition and selectivity of action on PDE-5 but their differences in activity, interaction with food and alcohol, biological half-life and other characteristics make their use individual for certain clinical situations. Our trial with participation of 575 patients (mean age 57.73 +/- 12.33 years) with arteriogenic erectile dysfunction and great number of vascular risk factors has shown that wardenafil was most popular among our examinees as it is more effective and begins acting faster. Further studies in optimization of the above drugs administration may perfect treatment of erectile dysfuncion.

• Authors: E B Mazo, S I Gamidov, V V Iremashvili, R V Gasanov
• Journal: Urologiia (Moscow, Russia : 1999) (Urologiia) 2009 Jan-Feb Issue 1 Pg. 40, 43-6 ISSN: 1728-2985 [Print] Russia (Federation)
• PMID: 19432232 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)

Chemical References

• Phosphodiesterase 5 Inhibitors
• Phosphodiesterase Inhibitors
• Cyclic Nucleotide Phosphodiesterases, Type 5

Topics

• Adult
• Cyclic Nucleotide Phosphodiesterases, Type 5 (metabolism)
• Humans
• Impotence, Vasculogenic (drug therapy, enzymology)
• Male
• Middle Aged
• Phosphodiesterase 5 Inhibitors
• Phosphodiesterase Inhibitors (administration & dosage, adverse effects)
• Risk Factors
• Substrate Specificity (drug effects)
• Vascular Diseases (chemically induced, enzymology)